Cargando…

Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice

BACKGROUND: Endometrial regenerative cells (ERCs) are mesenchymal-like stem cells that can be non-invasively obtained from menstrual blood and are easily grown /generated at a large scale without tumorigenesis. We previously reported that ERCs exhibit unique immunoregulatory properties in vitro, how...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Yongcheng, Xu, Xiaoxi, Zhang, Bai, Zhou, Guangying, Li, Hongyue, Du, Caigan, Han, Hongqiu, Wang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269937/
https://www.ncbi.nlm.nih.gov/pubmed/25475342
http://dx.doi.org/10.1186/s12967-014-0344-5
_version_ 1782349418031218688
author Lv, Yongcheng
Xu, Xiaoxi
Zhang, Bai
Zhou, Guangying
Li, Hongyue
Du, Caigan
Han, Hongqiu
Wang, Hao
author_facet Lv, Yongcheng
Xu, Xiaoxi
Zhang, Bai
Zhou, Guangying
Li, Hongyue
Du, Caigan
Han, Hongqiu
Wang, Hao
author_sort Lv, Yongcheng
collection PubMed
description BACKGROUND: Endometrial regenerative cells (ERCs) are mesenchymal-like stem cells that can be non-invasively obtained from menstrual blood and are easily grown /generated at a large scale without tumorigenesis. We previously reported that ERCs exhibit unique immunoregulatory properties in vitro, however their immunosuppressive potential in protecting the colon from colitis has not been investigated. The present study was undertaken to determine the efficacy of ERCs in mediating immunomodulatory functions against colitis. METHODS: Colitis was induced by 4% dextran-sulfate-sodium (DSS, in drinking water) in BALB/c mice for 7 days. ERCs were cultured from healthy female menstrual blood, and injected (1 million/mouse/day, i.v.) into mice on days 2, 5, and 8 following colitis induction. Colonic and splenic tissues were collected on day 14 post-DSS-induction. Clinical signs, disease activity index (DAI), pathological and immunohistological changes, cytokine profiles and cell populations were evaluated. RESULTS: DSS-induced mice in untreated group developed severe colitis, characterized by body-weight loss, bloody stool, diarrhea, mucosal ulceration and colon shortening, as well as pathological changes of intra-colon cell infiltrations of neutrophils and Mac-1 positive cells. Notably, ERCs attenuated colitis with significantly reduced DAI, decreased levels of intra-colon IL-2 and TNF-α, but increased expressions of IL-4 and IL-10. Compared with those of untreated colitis mice, splenic dendritic cells isolated from ERC-treated mice exhibited significantly decreased MHC-II expression. ERC-treated mice also demonstrated much less CD3(+)CD25(+) active T cell and CD3(+)CD8(+) T cell population and significantly higher level of CD4(+)CD25(+)Foxp3(+) Treg cells. CONCLUSIONS: This study demonstrated novel anti-inflammatory and immunosuppressive effects of ERCs in attenuating colitis in mice, and suggested that the unique features of ERCs make them a promising therapeutic tool for the treatment of ulcerative colitis.
format Online
Article
Text
id pubmed-4269937
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42699372014-12-18 Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice Lv, Yongcheng Xu, Xiaoxi Zhang, Bai Zhou, Guangying Li, Hongyue Du, Caigan Han, Hongqiu Wang, Hao J Transl Med Research BACKGROUND: Endometrial regenerative cells (ERCs) are mesenchymal-like stem cells that can be non-invasively obtained from menstrual blood and are easily grown /generated at a large scale without tumorigenesis. We previously reported that ERCs exhibit unique immunoregulatory properties in vitro, however their immunosuppressive potential in protecting the colon from colitis has not been investigated. The present study was undertaken to determine the efficacy of ERCs in mediating immunomodulatory functions against colitis. METHODS: Colitis was induced by 4% dextran-sulfate-sodium (DSS, in drinking water) in BALB/c mice for 7 days. ERCs were cultured from healthy female menstrual blood, and injected (1 million/mouse/day, i.v.) into mice on days 2, 5, and 8 following colitis induction. Colonic and splenic tissues were collected on day 14 post-DSS-induction. Clinical signs, disease activity index (DAI), pathological and immunohistological changes, cytokine profiles and cell populations were evaluated. RESULTS: DSS-induced mice in untreated group developed severe colitis, characterized by body-weight loss, bloody stool, diarrhea, mucosal ulceration and colon shortening, as well as pathological changes of intra-colon cell infiltrations of neutrophils and Mac-1 positive cells. Notably, ERCs attenuated colitis with significantly reduced DAI, decreased levels of intra-colon IL-2 and TNF-α, but increased expressions of IL-4 and IL-10. Compared with those of untreated colitis mice, splenic dendritic cells isolated from ERC-treated mice exhibited significantly decreased MHC-II expression. ERC-treated mice also demonstrated much less CD3(+)CD25(+) active T cell and CD3(+)CD8(+) T cell population and significantly higher level of CD4(+)CD25(+)Foxp3(+) Treg cells. CONCLUSIONS: This study demonstrated novel anti-inflammatory and immunosuppressive effects of ERCs in attenuating colitis in mice, and suggested that the unique features of ERCs make them a promising therapeutic tool for the treatment of ulcerative colitis. BioMed Central 2014-12-05 /pmc/articles/PMC4269937/ /pubmed/25475342 http://dx.doi.org/10.1186/s12967-014-0344-5 Text en © Lv et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lv, Yongcheng
Xu, Xiaoxi
Zhang, Bai
Zhou, Guangying
Li, Hongyue
Du, Caigan
Han, Hongqiu
Wang, Hao
Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice
title Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice
title_full Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice
title_fullStr Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice
title_full_unstemmed Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice
title_short Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice
title_sort endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269937/
https://www.ncbi.nlm.nih.gov/pubmed/25475342
http://dx.doi.org/10.1186/s12967-014-0344-5
work_keys_str_mv AT lvyongcheng endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice
AT xuxiaoxi endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice
AT zhangbai endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice
AT zhouguangying endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice
AT lihongyue endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice
AT ducaigan endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice
AT hanhongqiu endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice
AT wanghao endometrialregenerativecellsasanovelcelltherapyattenuateexperimentalcolitisinmice